Back to Search
Start Over
Epidemiology and long-term outcome in outpatients with chronic heart failure in Northwestern Europe.
- Source :
-
Heart (British Cardiac Society) [Heart] 2019 Aug; Vol. 105 (16), pp. 1252-1259. Date of Electronic Publication: 2019 Feb 21. - Publication Year :
- 2019
-
Abstract
- Objective: To describe the epidemiology, long-term outcomes and temporal trends in mortality in ambulatory patients with chronic heart failure (HF) with reduced (HFrEF), mid-range (HFmrEF) or preserved ejection fraction (HFpEF) from three European countries.<br />Methods: We identified 10 312 patients from the Norwegian HF Registry and the HF registries of the universities of Heidelberg, Germany, and Hull, UK. Patients were classified according to baseline left ventricular ejection fraction (LVEF) and time of enrolment (period 1: 1995-2005 vs period 2: 2006-2015). Predictors of mortality were analysed by use of univariable and multivariable Cox regression analyses.<br />Results: Among 10 312 patients with stable HF, 7080 (68.7%), 2086 (20.2%) and 1146 (11.1%) were classified as having HFrEF, HFmrEF or HFpEF, respectively. A total of 4617 (44.8%) patients were included in period 1, and 5695 (55.2%) patients were included in period 2. Baseline characteristics significantly differed with respect to type of HF and time of enrolment. During a median follow-up of 66 (33-105) months, 5297 patients (51.4%) died. In multivariable analyses, survival was independent of LVEF category (p>0.05), while mortality was lower in period 2 as compared with period 1 (HR 0.81, 95% CI 0.72 to 0.91, p<0.001). Significant predictors of all-cause mortality regardless of HF category were increasing age, New York Heart Association functional class, N-terminal pro-brain natriuretic peptide and use of loop diuretics.<br />Conclusion: Ambulatory patients with HF stratified by LVEF represent different phenotypes. However, after adjusting for a wide range of covariates, long-term survival is independent of LVEF category. Outcome significantly improved during the last two decades irrespective from type of HF.<br />Competing Interests: Competing interests: None declared.<br /> (© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.)
- Subjects :
- Adrenergic beta-Antagonists therapeutic use
Age Factors
Aged
Angiotensin Receptor Antagonists therapeutic use
Angiotensin-Converting Enzyme Inhibitors therapeutic use
Anticoagulants therapeutic use
Aspirin therapeutic use
Chronic Disease
Female
Germany epidemiology
Heart Failure metabolism
Heart Failure physiopathology
Heart Failure therapy
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use
Male
Middle Aged
Mineralocorticoid Receptor Antagonists therapeutic use
Multivariate Analysis
Natriuretic Peptide, Brain metabolism
Norway epidemiology
Outpatients
Peptide Fragments metabolism
Platelet Aggregation Inhibitors therapeutic use
Prognosis
Proportional Hazards Models
Registries
Sodium Potassium Chloride Symporter Inhibitors therapeutic use
United Kingdom epidemiology
Heart Failure epidemiology
Mortality trends
Stroke Volume
Subjects
Details
- Language :
- English
- ISSN :
- 1468-201X
- Volume :
- 105
- Issue :
- 16
- Database :
- MEDLINE
- Journal :
- Heart (British Cardiac Society)
- Publication Type :
- Academic Journal
- Accession number :
- 30792238
- Full Text :
- https://doi.org/10.1136/heartjnl-2018-314256